Close Menu

NEW YORK – NeoImmuneTech on Monday announced that the US Food and Drug Administration had accepted an investigational new drug application for the company's lead drug candidate, NT-I7, in combination with the CD19 CAR T-cell therapy tisagenlecleucel (Novartis' Kymriah) for patients with relapsed or refractory large B cell lymphoma.

Rockville, Maryland-based NeoImmuneTech will accordingly begin evaluating the safety, tolerability, and preliminary anti-tumor activity of the combination in a multicenter Phase I clinical trial.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.


NTRK fusions are oncogenic drivers in a variety of tumors.

Sponsored by

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Sponsored by

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.


In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.